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This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and
oxaliplatin-containing regimens. The initial dose of S-1 was 35mgm
 2, administered twice daily for 14 days every 3 weeks. Treatment
was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients
as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate
was 14.3% (95% CI, 0.4–28.1), and the disease control rate was 42.9% (95% CI, 23.3–62.4). With a median follow-up period of 227
days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all
patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In
conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of
35mgm
 2 was well tolerated and can be used in designing further combination chemotherapy.
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Colorectal cancer is the second leading cause of cancer deaths in
Western countries. In Korea, colorectal cancer is the fourth most
common malignancy, and its incidence is rising rapidly along with
the westernisation of life style (Kim et al, 2002). Thirty percent of
patients present with advanced disease, and one-half of patients
who have undergone surgery eventually develop metastasis. The
prognosis of metastatic disease is poor, although palliative
chemotherapy has been shown to prolong survival over best
supportive care (Glimelius et al, 1994). 5-Fluorouracil (5-FU) has
been widely used in the treatment of metastatic colorectal cancer,
and its modulation by leucovorin increased the response rate to
23%.
With the introduction of irinotecan and oxaliplatin during the
last decade, treatment choice for metastatic colorectal cancer has
been extended. Irinotecan or oxaliplatin combined with 5-FU
resulted in improved tumour response with a moderate survival
prolongation (De Gramont et al, 2000; Douillard et al, 2000; Saltz
et al, 2000). Moreover, there have been recent trials introducing
these agents in adjuvant therapy (Alberts et al, 2005; Tyagi et al,
2005). This rapid change in treatment strategy will ultimately lead
to a considerable increase in the number of patients with recurrent
or progressive disease who have been previously exposed to
irinotecan and oxaliplatin, and it raises the necessity for salvage
therapy for this patient group. Currently, chemotherapeutic option
for these patients is quite limited. Cetuximab is regarded to be a
promising option in this setting, and capecitabine is under study of
alternative dosing method for use in combination regimens, and
investigational agents such as bevacizumab have been tried
restrictively for selected patients (Cunningham et al, 2004; Saltz
et al, 2004; Gubanski et al, 2005; Matin et al, 2005).
Oral chemotherapy has advantages in the aspects of pharma-
coeconomics and patient preference. Oral fluoropyrimidines are
considered to be an alternative to conventional protracted 5-FU
infusion as far as they provide comparable efficacy and
compliance. A novel oral fluoropyrimidine, S-1, has been
developed to improve the therapeutic index of tegafur (FT), and
5-FU level was maintained high in plasma and tumour with less
gastrointestinal toxicity by combination with two biomodulators,
5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate
(Oxo). S-1 has shown promising activity in untreated colorectal
cancer through several phase II trials. And in a phase I study, S-1
led to objective response in heavily pretreated colorectal cancer
patients (Chu et al, 2004). Based on these results, we conducted
a phase II study to evaluate the possibility of S-1 as a salvage
option for heavily pretreated colorectal cancer patients who had
previously received irinotecan and oxaliplatin.
PATIENTS AND METHODS
Patient eligibility
The eligibility criteria were as follows: histologically proven colorectal
adenocarcinoma with metastatic, inoperable disease, Eastern
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sCooperative Oncology Group (ECOG) performance scale 0–2, docu-
mented disease progression during or within 6 months after treatment
with irinotecan- and oxaliplatin-containing regimens, at least one
unidimensionally measurable lesion as assessed by spiral computed
tomography outside any previously irradiated area, age X18 years old,
life expectancy X3 months, and adequate organ functions (WBC
X3000ml
 1, platelets X100000ml
 1,h a e m o g l o b i nX9.0gdl
 1,s e r u m
creatinine p1.5  of the upper limit of normal (ULN), bilirubin
p1.25  ULN, and serum aminotransferases p2.5  ULN). Patients
were excluded if they had other active malignancies, brain metastasis,
or severe comorbid conditions. After IRB approval, informed consent
from all patients was obtained before enrolment.
Treatment schedule
The starting dose of S-1 was twice daily at 35mgm
 2. S-1 was
administered within 1h after meals for 2 weeks, followed by a
1-week rest. The schedule was repeated until the occurrence of
disease progression, unacceptable toxicities, or patient‘s refusal. A
dose reduction of 10mgm
 2 a day was made if Xgrade 3
haematological or non-haematological toxicity was shown in the
previous cycle. Dose re-escalation was not allowed. Patients who
required more than 4 weeks of rest for recovery from any toxicity
other than alopecia, nausea, vomiting, or anaemia, or who required
dose reduction of more than two steps (total 20mgm
 2 a day),
were withdrawn from the study.
Evaluation of response and adverse event
Baseline evaluations included a complete medical history, physical
and radiologic examinations, performance status, complete blood
count (CBC), and biochemistries. During treatment, patients were
evaluated with a weekly CBC. Physical examination, performance
status, biochemistries were re-evaluated before each subsequent
cycle. Imaging studies for lesions were repeated every two cycles.
Treatment response was evaluated according to the guidelines
of the Response Evaluation Criteria in Solid Tumors (RECIST)
Committee. Patients were considered to be assessable for response
if they had evidence of early disease progression clinically or
radiologically before two cycles, or if they had received a minimum
of two cycles of treatment with at least one tumour measurement.
If a patient was documented as having a complete response (CR)
or a partial response (PR), a confirmatory evaluation was
performed after 4 weeks. Time to progression (TTP) was defined
as the interval from the first day of treatment until disease
progression, and overall survival (OS) was calculated from the first
day of treatment to death. All the patients were evaluated for
adverse events weekly. Adverse events were graded according to
the NCI-CTC scale (Version 3.0).
Statistics
Time-dependent variables were estimated with a log-rank test using
the Kaplan–Meier method. This study was designed using the
Minimax two-stage design (Simon, 1989). Sample size was calculated
with 80% power to detect an objective response rate of 15% (P1) and
to rule out a response rate of 3% (P0). The first stage was determined
with 18 patients, and the criterion for continued accrual was the
observation of at least one tumour response. The second stage was
planned to accrue a further 10 patients with two more responses. The
required number of patients was determined to be 28.
RESULTS
Patient characteristics
A total of 28 patients entered the study between July 2004 and
October 2005. Baseline patient characteristics are listed in Table 1.
Twenty-six patients were evaluable for tumour response. Two
patients refused treatment after the first cycle and withdrew the
consent. The median age was 56 years. All but four patients had
undergone prior resection of their primary tumour. Liver and lung
were the most common sites of measurable lesions, and peritoneal
seeding was the main site of non-measurable lesions. The average
diameter of target lesion was 26 (range 10–99mm) and the median
number of measurable lesions per patient was three (range 1–8).
Table 2 summarises the prior chemotherapy our patients
received. S-1 was administered as third-line therapy to 21 patients
and the remaining seven patients received S-1 as fourth-line
therapy. The median time from documentation of disease
progression (or relapse) of previous regimen to S-1 treatment
was 21 (range 10–84) days. The median cycle number of previous
chemotherapy was 18 (range 7–33) per patient, and that of
regimens containing irinotecan or oxaliplatin was 6, with a median
dose intensity of 0.98.
Treatment outcomes
A total of 125 treatment cycles (median 2, range 1–11) were
administered. The median daily dose administered was 120 (range
100–150) mg. Two patients were subjected to dose reduction
owing to adverse events. Seven patients voluntarily delayed their
subsequent cycle by 1 week without any significant toxicity. The
median dose intensity of all the patients was 317 (range 205–327)
mgm
 2week
 1. Seventeen patients (60.7%) were switched over to
the next chemotherapy regimens after disease progression was
documented.
Efficacy
Of the 26 patients evaluable for response, one CR and three PRs
were achieved, and eight patients had stable disease. The overall
Table 1 Patient characteristics
Patient characteristics Number of patients (%)
Number of enrolled patients 28
Number of evaluable patients 26
Median age (years) (range) 56 (32–69)
Male: female 15:13
ECOG performance status
0–1 8 (28.6)
2 20 (71.4)
Primary site
Colon 18 (64.3)
Rectum 10 (35.7)
Histological differentiation
Well moderate 25 (89.3)
Poor 3 (10.7)
Prior resection of primary site
Yes 23 (82.1)
No 5 (17.9)
Site of measurable lesions
Liver 49 (52.1)
Lung 30 (31.9)
Lymph node 12 (12.8)
Abdominal mass 3 (3.2)
Metastatic site per patient
1 10 (35.7)
2 12 (42.9)
X3 6 (21.4)
ECOG¼Eastern Cooperative Oncology Group.
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sresponse rate was 14.3% (95% CI, 0.4–28.1) and disease control
rate was 42.9% (95% CI, 23.3–62.4) by intent-to-treat analysis
(Table 3). All objective responses were documented after two
cycles of treatment and lasted 126, 195, 248, and 204þ days,
respectively. Metastatic sites in the liver and lung had a response
rate of 10.2 and 23.3%, respectively, whereas other sites showed no
objective tumour shrinkage. No difference in efficacy was observed
with respect to the size or the number of lesions.
Survival
With a median follow-up duration of 227 (range, 28–567) days, 24
patients (86%) showed disease progression and nine patients
(32%) expired from disease. Median TTP was 91 (95% CI, 9–173)
days (Figure 1). Median OS for all patients was 414 (95% CI, 336–
492) days, and the 1-year survival rate was 60.7%.
Safety
No grade 4 adverse event or treatment-related mortality was
observed. The most common haematologic adverse event was
anaemia without evidence of bleeding, which occurred in 14
patients (50%), with two patients receiving transfusions. Severe
neutropenia (grade X3) was reported in two patients. The most
common non-haematologic adverse event was nausea, which
affected 64% of patients. Adverse events were well managed and
self-limiting. Grade 3 adverse event amenable to dose reduction
was recorded in two patients, consisting of neutropenia and
Table 2 Summary of prior chemotherapy
Number of patients
Dose intensity Cycle
Total CR/PR SD PD Post-op
a Median (range) Median (range)
Adjuvant
5-FU+LV 6 — — — 6 1.00 6 (2–10)
First line
5-FU+LV 3 — — — 3 1.00 (0.94–1.00) 6 (6–12)
Irinotecan-based
b 11 4 1 1 5 0.98 (0.62–1.00) 6 (3–12)
Oxaliplatin-based
b 14 4 4 1 5 0.96 (0.84–1.00) 6 (2–9)
Second line
Irinotecan-based
c 15 8 5 2 — 0.93 (0.63–1.00) 6 (2–18)
Oxaliplatin-based
c 13 3 7 2 1 0.98 (0.82–1.00) 6 (2–12)
Third line
Irinotecan-based
d 2— 1 —1N A
e (0.94–1.00) NA
e (6–8)
Oxaliplatin-based
e 1— 1 — — N A
e (0.93) NA
e (4)
5-FU+cisplatin 1 — — 1 — NA
e (1.00) NA
e (2)
Capecitabine-based
f 3 — 1 2 — 1.00 (0.92–1.00) 3 (2–3)
5-FU¼5-fluorouracil; LV¼leucovorin; CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progressive disease; Post-op¼postoperative; NA¼not
assessable.
aRepresents in people who received chemotherapy after radical dissection of all visible lesions (R0 resection) of whether primary or metastasis. These patients do not
have measurable lesion, therefore their primary end point of treatment was recurrence.
bAll the patients received first-line treatment which were combined with 5-FU
continuous infusion modulated by leucovorin.
cAll but five patients received second-line treatment which were combined with 5-FU+leucovorin or capecitabine. The five patients
were in irinotecan group and received monotherapy.
dReceived iriotecan monotherapy, FORFIRI, and XELOX, respectively.
eMedian value was not obtainable owing to small
patient number.
fReceived monotherapy (two patients) and combined with mitomycin-C (one patient).
Table 3 Response to treatment
N CR PR SD PD NE Response rate (%) Disease control rate (%)
Overall 28 1 3 8 14 2 14.3 42.9
(95% CI) (0.4–28.1) (23.3–62.4)
Metastatic target sites
Liver 49 2 3 17 22 5 10.2 44.9
Lung 30 1 6 13 10 — 23.3 66.7
Others 15 — — 9 6 — 0.0 60.0
N¼number; CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progressive disease; NE¼not evaluable; CI¼confidence interval; 95% CI, 95% CI.
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Figure 1 Survival analysis of all patients (n¼28).
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sanaemia combined with neutropenia, respectively. Adverse events
associated with treatment are listed in Table 4.
DISCUSSION
Regimens including 5-FU with irinotecan, oxaliplatin, and
bevacizumab have proven effective in the treatment of colorectal
cancer as first-line and second-line treatment. However, there
have been few reports of satisfactory salvage therapy in heavily
pretreated patients. Novel target agents such as cetuximab have
been promising for their potential role as salvage therapy
(Cunningham et al, 2004). However, oral agents could be a
promising alternative when taking the patients’ general condition
and quality of life into consideration.
Capecitabine has recently been tried as salvage therapy, but the
efficacy was not satisfactory. Capecitabine showed no objective
response in 5-FU-resistant cancer in a phase II trial (Hoff et al,
2004). Combination with MMC resulted in a response rate of
15% in irinotecan-resistant cancer, but its efficacy fell to 5% when
the cancer was resistant to both irinotecan and oxaliplatin. Other
combinations with trimetrexate or irinotecan did not show any
additional benefit either (Chong et al, 2005; Gubanski et al, 2005;
Matin et al, 2005).
Integrating S-1 in colorectal cancer has been proposed in several
phase II studies. These studies reported a response of 24–40% with
a median TTP of 5–6 months when used as a first-line treatment
(Ohtsu et al, 2000; Van den Brande et al, 2003; Shirao et al, 2004).
Our study is the first one investigating the role of S-1 as a salvage
treatment in irinotecan- and oxaliplatin-pretreated colorectal
cancer. One of our concerns in designing this phase II trial was
the predictive efficacy of S-1. Our study was designed to show a
response rate of 15%, which is quite high considering the activity
of infusional 5-FU and capecitabine in chemotherapy exposed
patients. Nevertheless, this response rate is currently the minimum
response expected from any new agent targeting second- or third-
line treatment for colorectal cancer (Hoff et al, 2004; Gubanski
et al, 2005). Treatment schedule of S-1 was another point of
consideration. Japanese trials traditionally adopted 80mgm
 2, but
their actual dose is inconsistent with BSA (64–80mgm
 2) (Ohtsu
et al, 2000; Shirao et al, 2004). Meanwhile, Western studies are BSA
consistent. However, in a sole European phase II trial, a dose of
80mgm
 2 had to be reduced owing to significant non-haemato-
logical toxicity. We adopted 70mgm
 2 and a 3-week schedule for
the purpose of procuring adequate dose intensity and compliance
even in heavily exposed patients to chemotherapy. With this
dosage system, we could attain high-dose intensity of
317mgm
 2week
 1 (97%).
Preclinical modelling gave several evidence that S-1 would be
effective even in pretreated colorectal cancer. S-1 showed higher
tumour growth inhibition than UFT did in an orthotopic
implantation model of colon cancer, and S-1 promoted antitumour
activity in chemoresistant cancer cells in vitro (Shirasaka et al,
1996). In a phase I study, S-1 resulted in objective antitumour
activity in heavily-pretreated colorectal carcinoma, and there was a
report that S-1 led to a CR in 5-FU-resistant gastric cancer (Chu
et al, 1994; Tsukioka et al, 2001). All of these findings were the
basis of our designing phase II trial, and we observed a response
rate of near 15%, which imposes a promise of S-1 for heavily
pretreated patients. It is difficult to clarify the mechanisms behind
the effectiveness of S-1, which are different from those of other 5-
FU modulators. Higher plasma or intratumoural concentrations of
5-FU could be obtained from inhibition of dihydropyrimidine
dehydrogenase by CDHP compared to simple 5-FU infusion. The
inhibitory effect of CDHP on the production of a-fluoro-b-alanine
might be another explanation, as it was reported to reduce the
antitumour effect of 5-FU (Cao et al, 2000).
From the perspective of survival, four patients who obtained
objective tumour response had a median response duration of 200
days, suggesting that antitumour activity of S-1 was durable even
in heavily treated patients once response was induced. The median
TTP was 91 days, which is comparable to previously reported
third-line therapy. It is surprising that OS was more than 400 days.
This result might come from patient selection mechanisms
irrespective of therapeutic effects of S-1. But, S-1 treatment
showed favourable safety profiles even in heavily pretreated
setting, resulting in median dose intensity of 97% and over 60%
of patients were switched to yet other salvage regimens including
Table 4 Adverse events per patient
Number of patients (N¼28)
Grade 1 Grade 2 Grade 3 Toxicity of all grades (%) Toxicity of grade 3 (%)
Hematologic toxicity
Anaemia 7 6 1 50.0 3.6
Leucopenia 7 4 — 39.3 —
Neutropenia 4 3 2 32.1 7.1
Thrombocytopenia 5 — — 17.9 —
Non-hematologic toxicity
Diarrhoea 8 2 — 35.7 —
Nausea 16 2 — 64.3 —
Vomiting 9 1 — 35.7 —
Mucositis 9 2 — 39.3 —
Anorexia 16 1 — 60.7 —
Fatigue 7 1 — 28.6 —
Weight loss 5 3 — 28.6 —
Dyspepsia 7 — — 25.0 —
Skin rash 3 — — 10.7 —
Itching sensation 4 — — 14.3 —
Skin pigmentation 9 2 — 39.3 —
Hand-and-foot syndrome 9 1 — 35.7 —
Abdominal pain 10 1 — 39.3 —
Elevated creatinine 2 — — 7.1 —
Changes in liver function 13 4 — 60.7 —
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scetuximab, capecitabine, or other novel investigational agents after
failure of S-1. This suggests that patients could maintain their
performance status during S-1 treatment enough to tolerate next
regimen and that S-1 rarely affected the patients’ compliance and
quality of life. It is noticeable that the group previously exposed
to capecitabine had a tendency of shorter TTP compared to the
capecitabine-naı ¨ve group (38 days vs 111 days, P¼0.33). Although
not statistically significant owing to the small number of patients,
this result implies that resistance to capecitabine may adversely
influence the efficacy of S-1, and it should be an eligibility
consideration for future clinical trial design.
In conclusion, this first phase II study of S-1 in irinotecan- and
oxaliplatin-pretreated colorectal carcinoma demonstrated high-
dose intensity, promising efficacy and survival with favourable
safety profile. S-1 shows potential activity as a salvage therapy in
heavily pretreated colorectal cancer. Dose of 35mgm
 2 twice daily
is feasible and can be used in designing further combination
chemotherapy.
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